Pharmaceuticals

Global VELETRI Market Report 2026: Emerging Trends and Growth Scenarios

February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the veletri market from 2026–2035 with trusted insights from The Business Research Company

How is the VELETRI Market size predicted to change over the forecast window of 2026–2035?

The veletri market has experienced substantial expansion in recent years. It is forecast to grow from $1.45 billion in 2025 to $1.56 billion in 2026, at a compound annual growth rate (CAGR) of 7.7%. The historical market growth can be attributed to the clinical effectiveness of epoprostenol, an increase in the diagnosis of PAH, hospitals’ reliance on IV prostacyclins, limited available oral alternatives, and enhanced PAH survival rates.

The veletri market is projected to experience robust expansion over the coming years, reaching $2.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period is primarily driven by factors such as a rise in pah prevalence, the expansion of specialty pah centers, an increasing need for stable formulations, wider adoption of infusion therapy, and enhanced awareness of pah. Key developments expected in this period encompass a growing uptake of non-refrigerated prostacyclin treatments, more widespread application of continuous infusion pah therapies, an escalating demand for advanced pah vasodilators, the broadening of hospital-based pah management, and a heightened emphasis on enhancing pah patient mobility.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21314&type=smp

Which Drivers Are Contributing To The Expansion Of The VELETRI Market?

The VELETRI market is anticipated to expand propelled by the growing incidence of venous diseases. These conditions involve impaired blood flow within veins, leading to symptoms such as swelling, pain, and potential complications like varicose veins and deep vein thrombosis. The rising occurrence of venous diseases is influenced by factors including an aging population, inactive lifestyles, obesity, and advancements in diagnostic methods. VELETRI is employed to enhance exercise capability and alleviate symptoms in individuals experiencing venous diseases that impact the pulmonary vasculature. For instance, in January 2025, the Centers for Disease Control and Prevention, a US-based government organization, reported that up to 900,000 individuals in the United States are affected annually by venous thromboembolism (VTE), a condition characterized by blood clots, resulting in an estimated 60,000 to 100,000 fatalities attributed to VTE each year. Therefore, the increasing prevalence of venous diseases is a key factor driving the growth of the VELETRI market.

What Segment Classifications Make Up The VELETRI Market?

The veletri market covered in this report is segmented –

1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation

2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution

2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution

Which Trends Are Shaping Activity Within The VELETRI Market?

Leading firms in the Veletri market are concentrating on increasing availability through generic drug versions, specifically FDA-approved epoprostenol sodium injection, to offer economical treatment solutions for individuals suffering from pulmonary arterial hypertension. Generic Veletri denotes formulations of the branded epoprostenol product that are therapeutically identical, adhering to FDA requirements for quality, safety, and effectiveness, thereby delivering comparable clinical advantages at a reduced price. As an illustration, in October 2025, Mylan Pharmaceuticals, a pharmaceutical company based in the US, obtained FDA approval for its generic Veletri (epoprostenol sodium) injection. This product is provided in various vial strengths, such as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and exhibits the identical prostacyclin mimetic activity as the original branded form, aiding in the enhancement of exercise tolerance and the control of symptoms for PAH patients.

Which Major Firms Are Strengthening Their Position In The VELETRI Market?

Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The VELETRI Market?

North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized VELETRI Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21314&type=smp

Browse Through More Reports Similar to the Global VELETRI Market 2026, By The Business Research Company

Vermiculite Market Report 2026

https://www.thebusinessresearchcompany.com/report/vermiculite-global-market-report

Vanadium Market Report 2026

https://www.thebusinessresearchcompany.com/report/vanadium-global-market-report

Gelatin Market Report 2026

https://www.thebusinessresearchcompany.com/report/gelatin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795